IMLFF - InMed Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.5828
-0.0533 (-8.38%)
As of 2:33PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.6361
Open0.6320
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.5750 - 0.6400
52 Week Range0.1770 - 1.9500
Volume733,881
Avg. Volume547,595
Market Cap97.548M
Beta-1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.0420
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter's Over-Allotment Option
    CNW Group25 days ago

    InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter's Over-Allotment Option

    OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has closed the "bought deal" financing (the "Financing") originally announced on June 12, 2018 , and that the over-allotment option of the underwriter, Eight Capital, has been exercised in full.  The total gross proceeds raised by the Company in the Financing were C$14.95 million . Due to high investor demand, the Financing was up-sized from its original amount of C$10 million to C$13 million , and the 15% over-allotment option was exercised in full, bringing the total gross proceeds of the Financing to C$14.95 million .

  • InMed to Present at the 8th Annual LD Micro Invitational Conference
    CNW Group2 months ago

    InMed to Present at the 8th Annual LD Micro Invitational Conference

    A live webcast of the presentation will be available on InMed's website. InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

  • Interested In InMed Pharmaceuticals Inc (FRA:MWG2)? Here’s How It Performed Recently
    Simply Wall St.2 months ago

    Interested In InMed Pharmaceuticals Inc (FRA:MWG2)? Here’s How It Performed Recently

    Investors with a long-term horizong may find it valuable to assess InMed Pharmaceuticals Inc’s (DB:MWG2) earnings trend over time and against its industry benchmark as opposed to simply looking atRead More...

  • InMed Files Patent Application for INM-085 Glaucoma Program
    CNW Group2 months ago

    InMed Files Patent Application for INM-085 Glaucoma Program

    OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced it has filed a Patent Cooperation Treaty ("PCT") application for INM-085 as a cannabinoid-based topical therapy for glaucoma, which includes protection of its technology in about 150 different countries including the United States , and claims a priority date from May 8, 2018 (PCT/CA2018/050548). The PCT filing, which is a conversion from the provisional patent filed in May, 2017, is an important step in providing intellectual and commercial protection for this therapy. InMed is developing a stimulus-responsive, nanoparticle-laden vehicle for controlled delivery of ophthalmic drugs into the aqueous humor of the eye. The first applications of this vehicle will be for INM-085 as a cannabinoid-based topical therapy to reduce the intraocular pressure associated with glaucoma.

  • InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update
    CNW Group2 months ago

    InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update

    InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update

  • OTC Markets Group Welcomes InMed Pharmaceuticals Inc. to OTCQX
    PR Newswire2 months ago

    OTC Markets Group Welcomes InMed Pharmaceuticals Inc. to OTCQX

    NEW YORK , May 4, 2018 /PRNewswire/ --  OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced InMed Pharmaceuticals Inc. (TSX: IN; OTCQX: ...

  • InMed Appoints Dr. Vikramaditya G. Yadav to Scientific Advisory Board
    CNW Group2 months ago

    InMed Appoints Dr. Vikramaditya G. Yadav to Scientific Advisory Board

    InMed Appoints Dr. Vikramaditya G. Yadav to Scientific Advisory Board

  • CNW Group3 months ago

    InMed Rings the Opening Bell at the Toronto Stock Exchange

    InMed Rings the Opening Bell at the Toronto Stock Exchange

  • InMed Announces Appointment of Joshua Blacher as Chief Business Officer
    CNW Group3 months ago

    InMed Announces Appointment of Joshua Blacher as Chief Business Officer

    InMed Announces Appointment of Joshua Blacher as Chief Business Officer

  • InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange
    PR Newswire4 months ago

    InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange

    Trading on the TSX will commence March 26, 2018 VANCOUVER , March 23, 2018 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE:IN; OTCQB:IMLFF), a biopharmaceutical ...

  • InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange
    CNW Group4 months ago

    InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange

    InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange

  • InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development
    PR Newswire4 months ago

    InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development

    CSE: IN OTCQB: IMLFF VANCOUVER , March 13, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing ...

  • InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development
    CNW Group4 months ago

    InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development

    InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development

  • PR Newswire4 months ago

    InMed to Present at 30th Annual ROTH Capital Conference

    OTCQB: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today that Eric A. Adams, CEO & President, will be presenting to U.S. institutional investors at the 30th Annual ROTH Conference, which is being held March 11-14, 2018, at the Ritz Carlton, Laguna Niguel, California.  InMed's presentation at the conference is currently scheduled for Tuesday, March 13th, at 3:30 PM, PST. InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.

  • CNW Group4 months ago

    InMed to Present at 30th Annual ROTH Capital Conference

    InMed to Present at 30th Annual ROTH Capital Conference

  • PR Newswire4 months ago

    InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research

    OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today the publication of a peer-reviewed article in Drug Delivery and Translational Research. The article, titled "A stimulus-responsive, in situ forming, nanoparticle-laden hydrogel for ocular drug delivery", presents results from a pre-clinical study co-sponsored by InMed and was co-authored by Dr. Sazzad Hossain, InMed's Chief Scientific Officer.

  • CNW Group4 months ago

    InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research

    InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research

  • InMed Receives Conditional Approval to List on the Toronto Stock Exchange
    PR Newswire4 months ago

    InMed Receives Conditional Approval to List on the Toronto Stock Exchange

    OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to list its common shares ("Common Shares") on the TSX.  Final approval of the listing on the TSX remains subject to InMed fulfilling certain customary listing conditions of the TSX on or before the TSX-imposed deadline of May 29, 2018.  The Company expects that it will satisfy such conditions in advance of the TSX-imposed deadline. Upon listing on the TSX, the Common Shares will continue to trade under the symbol 'IN'.

  • InMed Receives Conditional Approval to List on the Toronto Stock Exchange
    CNW Group4 months ago

    InMed Receives Conditional Approval to List on the Toronto Stock Exchange

    InMed Receives Conditional Approval to List on the Toronto Stock Exchange

  • CNW Group6 months ago

    InMed Closes Over-Subscribed C$9.4 Million Financing

    InMed Closes Over-Subscribed C$9.4 Million Financing

  • Newsfile7 months ago

    CannabisNewsWire Announces Publication on Increased Investment Activity in Cannabis

    New York, New York--(Newsfile Corp. - December 22, 2017) - CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of CNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.The publication titled, "Pot Stock Bull Market Primed for Even ...

  • Newsfile7 months ago

    CannabisNewsWire Announces Publication Discussing Biotech's Leading Role in the Cannabis Industry

    New York, New York--(Newsfile Corp. - December 21, 2017) - CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of CNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.The publication, titled, "Biotech Market Banking on Big Cannabis Returns," ...

  • CNW Group7 months ago

    InMed Announces Non-Brokered Private Placement

    InMed Announces Non-Brokered Private Placement